Key result
Anticoagulation was administered in 34.0% of critically ill patients with atrial fibrillation and did not affect morbidity or mortality outcomes.
Why the study?
Little is known about the risk/benefit ratio of prescribing anticoagulation to patients with AF in intensive care, where CHA 2 DS 2 VASc and HAS-BLED scores are not validated.
Does therapeutic anticoagulation affect morbidity or mortality, and do standard risk scores correlate with thromboembolic and bleeding events in critically ill patients with atrial fibrillation?
Population
Critically ill patients admitted to intensive care with AF episodes during admission
Comparison
New onset AF vs known AF anticoagulation strategies
Design
Retrospective observational study
Authors
Loading...
Should not yet guide anticoagulation by standard scores in ICU AF; hypothesis-generating for ICU-specific risk tools.
Observational
Does therapeutic anticoagulation affect morbidity or mortality, and do standard risk scores correlate with thromboembolic and bleeding events in critically ill patients with atrial fibrillation?
Standard AF risk scores (CHA2DS2VASc and HAS-BLED) do not correlate well with clinical events in the ICU, suggesting current anticoagulation guidelines may not be directly transferable to critically ill patients.
Miller et al. (2022) conducted an observational in Atrial Fibrillation in critically ill patients. Anticoagulation vs. No anticoagulation was evaluated on Morbidity or mortality outcomes. Anticoagulation was administered in 34.0% of critically ill patients with atrial fibrillation and did not affect morbidity or mortality outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: